SCHEMBL15219285

SCHEMBL15219285

Cc1cccc(COc2ccc(C)cc2C(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.49
IDO1 P14902 2/20 0.49
FFAR4 Q5NUL3 1/20 0.48
MRGPRX4 Q96LA9 4/20 0.48
MAOA P21397 1/20 0.44
HTR6 P50406 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
CCR5 P51681 1/20 0.43
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NOD2 Q9HC29 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11919264 0.90 MRGPRX4 (0.45) MAOBIDO1FFAR4MRGPRX4LMNA
SCHEMBL13957662 0.89 MAPT (0.50) FFAR4MRGPRX4HTR6CCR5LMNA
SCHEMBL11916164 0.86 MRGPRX4 (0.48) MAOBFFAR4MRGPRX4LMNAMAPT
SCHEMBL9946034 0.79 FFAR4 (0.55) MAOBIDO1FFAR4MRGPRX4MAOA
SCHEMBL9946064 0.79 MAOB (0.47) MAOBIDO1FFAR4MRGPRX4MAOA
SCHEMBL9945918 0.78 L3MBTL1 (0.46) ADRA1ALMNAMAPTHPGDMAPK1
SCHEMBL13929791 0.78 MAOB (0.59) MAOBIDO1FFAR4MRGPRX4HTR1A
SCHEMBL6957559 0.77 MRGPRX4 (0.54) MAOBIDO1FFAR4MRGPRX4MAPT
SCHEMBL29951117 0.75 ENPP2 (0.55) MAOBIDO1FFAR4MRGPRX4MAOA
SCHEMBL12337611 0.75 MAPT (0.49) MAOBFFAR4MRGPRX4HTR6CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3210609-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2017-08-30 EP disclosed
US-20170218000-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. 2017-08-03 US disclosed
US-9273077-B2 Phosphorus derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2016-03-01 US disclosed
US-8912330-B2 Azaindole derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-12-16 US disclosed
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. 2014-12-11 US disclosed
US-20140066406-A1 Phosphorus Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-03-06 US disclosed
US-20130225528-A1 Phosphorus Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2013-08-29 US disclosed
US-20110294806-A1 AZAINDOLE DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066406-A1 Phosphorus Derivatives as Kinase Inhibitors PHKA1, PIK3CA, PHKA2 MAOB 4311/4885IDO1 4723/4885FFAR4 2851/4885
US-20170218000-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS MAP3K6, PIK3CA, MAP3K20 MAOB 3613/4885IDO1 4128/4885FFAR4 3974/4885
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors MAP3K5, MAP3K15, MAP4K2 MAOB 1450/4885IDO1 3216/4885FFAR4 3674/4885
US-20110294806-A1 AZAINDOLE DERIVATIVES AS KINASE INHIBITORS ABL1, CDKN1A, MAP3K13 MAOB 674/4885IDO1 706/4885FFAR4 3709/4885
US-20130225528-A1 Phosphorus Derivatives as Kinase Inhibitors PHKA1, PIK3CA, PHKA2 MAOB 4311/4885IDO1 4723/4885FFAR4 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.